BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29912760)

  • 1. The Role of Insulin-like Growth Factor (IGF) Axis in Early Diagnosis of Pancreatic Adenocarcinoma (PDAC).
    Wlodarczyk B; Gasiorowska A; Malecka-Panas E
    J Clin Gastroenterol; 2018 Aug; 52(7):569-572. PubMed ID: 29912760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.
    Kolb A; Rieder S; Born D; Giese NA; Giese T; Rudofsky G; Werner J; Büchler MW; Friess H; Esposito I; Kleeff J
    Cancer Biol Ther; 2009 Aug; 8(16):1527-33. PubMed ID: 19571666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Oncologic Impact of New-Onset Diabetes Mellitus on Recurrence in Resected Pancreatic Ductal Adenocarcinoma: A Comparison With Long-standing and Non-Diabetes Mellitus Patients.
    Lee S; Hwang HK; Kang CM; Lee WJ
    Pancreas; 2018 Aug; 47(7):816-822. PubMed ID: 29975349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients.
    Dugnani E; Gandolfi A; Balzano G; Scavini M; Pasquale V; Aleotti F; Liberati D; Di Terlizzi G; Petrella G; Reni M; Doglioni C; Bosi E; Falconi M; Piemonti L
    Pancreatology; 2016; 16(5):844-52. PubMed ID: 27546476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 Diabetes Mellitus and Its Association with the Risk of Pancreatic Carcinogenesis: A Review.
    Biadgo B; Abebe M
    Korean J Gastroenterol; 2016 Apr; 67(4):168-77. PubMed ID: 27112242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adaptor protein CrkII regulates IGF-1-induced biological behaviors of pancreatic ductal adenocarcinoma.
    Liu R; Wang Q; Xu G; Li K; Zhou L; Xu B
    Tumour Biol; 2016 Jan; 37(1):817-22. PubMed ID: 26250463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical profiles and long-term outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus.
    Ben Q; Xu M; Jiang Y; Yuan Y; Wang K; Fang J; Li Z
    Diabetes Metab Res Rev; 2012 Feb; 28(2):169-76. PubMed ID: 22423386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
    Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
    Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.
    Polvani S; Tarocchi M; Tempesti S; Bencini L; Galli A
    World J Gastroenterol; 2016 Feb; 22(8):2441-59. PubMed ID: 26937133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes.
    Włodarczyk B; Borkowska A; Włodarczyk P; Małecka-Panas E; Gąsiorowska A
    Prz Gastroenterol; 2021; 16(1):36-42. PubMed ID: 33986886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells.
    Dong Q; Li C; Che X; Qu J; Fan Y; Li X; Li Y; Wang Q; Liu Y; Yang X; Qu X
    Oncotarget; 2016 Dec; 7(50):82338-82353. PubMed ID: 27494897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers.
    Camidge DR; Dziadziuszko R; Hirsch FR
    Clin Lung Cancer; 2009 Jul; 10(4):262-72. PubMed ID: 19632946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma.
    Grace SA; Meeks MW; Chen Y; Cornwell M; Ding X; Hou P; Rutgers JK; Crawford SE; Lai JP
    Anticancer Res; 2017 Feb; 37(2):699-703. PubMed ID: 28179319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia.
    Hirakawa T; Yashiro M; Doi Y; Kinoshita H; Morisaki T; Fukuoka T; Hasegawa T; Kimura K; Amano R; Hirakawa K
    PLoS One; 2016; 11(8):e0159912. PubMed ID: 27487118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma.
    Chu CK; Mazo AE; Sarmiento JM; Staley CA; Adsay NV; Umpierrez GE; Kooby DA
    J Am Coll Surg; 2010 Apr; 210(4):463-73. PubMed ID: 20347739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
    Abbruzzese JL; Andersen DK; Borrebaeck CAK; Chari ST; Costello E; Cruz-Monserrate Z; Eibl G; Engleman EG; Fisher WE; Habtezion A; Kim SK; Korc M; Logsdon C; Lyssiotis CA; Pandol SJ; Rustgi A; Wolfe BM; Zheng L; Powers AC
    Pancreas; 2018; 47(5):516-525. PubMed ID: 29702529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes mellitus does not impact on clinically relevant pancreatic fistula after partial pancreatic resection for ductal adenocarcinoma.
    Malleo G; Mazzarella F; Malpaga A; Marchegiani G; Salvia R; Bassi C; Butturini G
    Surgery; 2013 May; 153(5):641-50. PubMed ID: 23276391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer.
    Mutgan AC; Besikcioglu HE; Wang S; Friess H; Ceyhan GO; Demir IE
    Mol Cancer; 2018 Feb; 17(1):66. PubMed ID: 29475434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.
    An W; Ben QW; Chen HT; Zheng JM; Huang L; Li GX; Li ZS
    Ann Surg Oncol; 2012 Nov; 19(12):3971-8. PubMed ID: 22622471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.